Log in

Relevant bibliographies by topics / Ovarian cancer, chemotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Ovarian cancer, chemotherapy.

Journal articles on the topic 'Ovarian cancer, chemotherapy'

Author: Grafiati

Published: 24 April 2022

Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ovarian cancer, chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Christian, J., and H. Thomas. "Ovarian cancer chemotherapy." Cancer Treatment Reviews 27, no. 2 (2001): 99–109. http://dx.doi.org/10.1053/ctrv.2001.0219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Friedrich, Michael, Alexander Khudyakov, Arne Terjung, Wolfgang Zinn, and Ulrich Füllers. "Influence of hyperthermic intraperitoneal chemotherapy (HIPEC) on the onset of adjuvant chemotherapy in ovarian cancer." Voprosy ginekologii, akušerstva i perinatologii 21, no. 2 (2022): 14–17. http://dx.doi.org/10.20953/1726-1678-2022-2-14-17.

Full text

Abstract:

Objective. To determine the benefits of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian cancer. Patients and methods. The study included 87 patients, while 74 patients had epithelial ovarian cancer and 13 patients showed other neoplasms. At the end of the operation, a 1-hour perfusion of the abdominal cavity was performed with cisplatin 50 mg/m2 at a temperature of 41°C. The patient data was retrospectively analyzed considering the time interval of postoperative chemotherapy based on the guideline. Results. Sixty patients manifested macrosc

APA, Harvard, Vancouver, ISO, and other styles

3

Mayomba, Colman, Godfrey Kaizilege, Richard Kiritta, et al. "Metachronous Ovarian Cancer after a Radical Hysterectomy with Ovarian Conservation for Early-Stage Cervical Cancer: A Case Report." International Journal of Medical Case Reports and Reviews 2, no. 4 (2023): 1–5. http://dx.doi.org/10.59657/2837-8172.brs.23.023.

Full text

Abstract:

Introduction: Cervical cancer is the fourth most common disease in women worldwide and the leading cause in Tanzania, with 9,772 new cases and 6,695 deaths annually. Surgery is better than radiation or chemotherapy for early-stage cervical cancer (stages IA2–IIA1). Due to the risks of oophorectomy in young women, ovarian conservation is crucial. Metachronous ovarian cancer is understudied, however, ovarian conservation does not enhance cervical cancer mortality. Clinical presentation: We report a rare case of recurrent metachronous ovarian cancer in a 42-year-old female, Para 3, Living 3, who

APA, Harvard, Vancouver, ISO, and other styles

4

OCHIAI, Kazunori. "Chemotherapy for Ovarian Cancer." Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 29, no. 4 (2004): 685–89. http://dx.doi.org/10.4030/jjcs1979.29.4_685.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lim, Myong Cheol, and Sang-Yoon Park. "Chemotherapy for ovarian cancer." Journal of the Korean Medical Association 59, no. 3 (2016): 175. http://dx.doi.org/10.5124/jkma.2016.59.3.175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kaye, S. B. "Chemotherapy for ovarian cancer." European Journal of Cancer 29, no. 4 (1993): 632–35. http://dx.doi.org/10.1016/s0959-8049(05)80168-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gamal, Abdul Hamid, Saleh Hadi Amani, and Ali Yeslam Nadia. "Ovarian cancer in southeastern of Yemen." GSC Advanced Research and Reviews 10, no. 3 (2022): 047–51. https://doi.org/10.5281/zenodo.6401099.

Full text

Abstract:

<strong>Introduction: </strong>Ovarian cancer is an important cause of mortality in women. The incidence of ovarian cancer and survival rates are still relatively unknown in southeast Yemen. This study takes into account trends in ovarian cancer incidence and survival rates by examining age, histological subtypes, residency, and treatment. <strong>Methods:</strong> The National Cancer Center Aden is the premier cancer care transformation center in the southeastern governorates and the source for collecting data on ovarian cancer mortality from 2014-2020 from the Surveillance, Epidemi

APA, Harvard, Vancouver, ISO, and other styles

8

Lowe, Thomas, and Robert J. Morgan. "Intraperitoneal Chemotherapy of Ovarian Cancer." Women's Health 3, no. 4 (2007): 433–40. http://dx.doi.org/10.2217/17455057.3.4.433.

Full text

Abstract:

Ovarian cancer is the leading cause of death among cancers of the female reproductive tract. Most women present with regionally advanced intraperitoneal disease with superficial spread of tumor along the peritoneal surfaces. Distant metastasis rarely occurs until late in the disease process; however, long-term survival of patients with advanced disease remains poor. Intraperitoneal chemotherapy allows higher concentration and prolonged half-life of chemotherapy within the peritoneal cavity compared with intravenous administration, while therapeutic intravenous concentrations are obtained. Thre

APA, Harvard, Vancouver, ISO, and other styles

9

Dressman, Holly K., Andrew Berchuck, Gina Chan, et al. "An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer." Journal of Clinical Oncology 25, no. 5 (2007): 517–25. http://dx.doi.org/10.1200/jco.2006.06.3743.

Full text

Abstract:

Purpose The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease. Patients and Methods A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample extern

APA, Harvard, Vancouver, ISO, and other styles

10

Dood, Robert, Nicole D. Fleming, Robert L. Coleman, Shannon Neville Westin, and Anil Sood. "When advanced ovarian cancer is not ovarian cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e17066-e17066. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17066.

Full text

Abstract:

e17066 Background:Tissue diagnosis of advanced ovarian cancer (OC) is not universally obtained prior to up-front surgery. This study sought to investigate non-OC cases discovered in the systemic laparoscopic (LSC) workup of presumed advanced OC. Methods: A prospective cohort of presumed advanced OC patients (based on elevated CA125 and/or imaging) presenting to our center without confirmed pathologic diagnosis. Patients with non-OC pathology confirmed in workup were characterized and compared to those with confirmed ovarian pathology using standard statistical tests. Results: 365 patients pres

APA, Harvard, Vancouver, ISO, and other styles

11

Sekine, Katsutoshi, Tetsuya Hamaguchi, Hirokazu Shoji, et al. "Retrospective analysis of the effects of systemic chemotherapy to the ovarian metastases from colorectal cancer." Journal of Clinical Oncology 35, no. 4_suppl (2017): 731. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.731.

Full text

Abstract:

731 Background: Ovarian metastases from colorectal cancers are relatively rare. Since most ovarian metastases are also associated with other metastatic sites, the prognosis is reported to be poor. It is not fully understood whether the response to systemic chemotherapy of ovarian metastases differs from that to other metastatic sites. Methods: We retrospectively reviewed the clinical data of patients with ovarian metastases from colorectal cancer treated at our hospital between January 2006 and December 2015. Results: Among the 635 female patients with relapsed or metastatic colorectal cancer,

APA, Harvard, Vancouver, ISO, and other styles

12

Afrăsânie, Vlad-Adrian, Alexandra Rusu, Adelina Silvana Gheorghe, et al. "Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib." Diagnostics 14, no. 17 (2024): 1898. http://dx.doi.org/10.3390/diagnostics14171898.

Full text

Abstract:

Ovarian cancer is one of the most frequent malignancies in women. The treatment landscape underwent significant changes as new agents were introduced in ovarian cancer management over the last decade. We present two cases of long responses to Olaparib in BRCA (BReast CAncer gene) mutant ovarian cancer patients. The first case belongs to a 42-year-old female diagnosed with advanced ovarian carcinoma with a rare germinal mutation (BRCA1 c.68_69delAG, commonly found in descendants of Ashkenazi Jewish populations, but also Arabic and Asian ones) and a significant family history of ovarian and brea

APA, Harvard, Vancouver, ISO, and other styles

13

Patel, Ami, Puja Iyer, Shinya Matsuzaki, Koji Matsuo, Anil K. Sood, and Nicole D. Fleming. "Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer." Cancers 13, no. 4 (2021): 626. http://dx.doi.org/10.3390/cancers13040626.

Full text

Abstract:

Epithelial ovarian cancer remains a leading cause of death amongst all gynecologic cancers despite advances in surgical and medical therapy. Historically, patients with ovarian cancer underwent primary tumor reductive surgery followed by postoperative chemotherapy; however, neoadjuvant chemotherapy followed by interval tumor reductive surgery has gradually become an alternative approach for patients with advanced-stage ovarian cancer for whom primary tumor reductive surgery is not feasible. Decision-making about the use of these approaches has not been uniform. Hence, it is essential to identi

APA, Harvard, Vancouver, ISO, and other styles

14

Wang, Wanqi (Jady), Veronika Bandara, Noor A. Lokman, et al. "Abstract 6320: CAR-T cells targeting LGR5: An effective treatment for chemotherapy resistant ovarian cancer." Cancer Research 84, no. 6_Supplement (2024): 6320. http://dx.doi.org/10.1158/1538-7445.am2024-6320.

Full text

Abstract:

Abstract Ovarian cancer is the second leading cause of cancer-related mortality among gynaecological cancers in the Western world. CAR-T cell therapy is an adoptive immunotherapy used to treat some blood cancers. This study has investigated whether leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) is a suitable target for CAR-T cell therapy for ovarian cancer. We assessed the cytotoxic effects of LGR5-targeting CAR-T cells on a range of ovarian cancer cell lines and primary serous ovarian cancer cells derived from patient ascites (at diagnosis and following relapse with chemot

APA, Harvard, Vancouver, ISO, and other styles

15

Abbas Abdulmueed Mustafa Alani, Ihab Q. Ali, and Yasir Khaleel Almusawi. "Changes in the Cancer Antigen Markers in the Pleural Liquid During Chemotherapy among Ovarian Cancer Patients." Indian Journal of Forensic Medicine & Toxicology 15, no. 4 (2021): 2978–83. http://dx.doi.org/10.37506/ijfmt.v15i4.17179.

Full text

Abstract:

The silent killer or ovarian cancer (OC) is one of the major causes of cancer deaths among women in themodern age. In view of the therapeutic roles of platinum based chemotherapy among the ovarian cancerpatients, objective of this report was to assess the effects of the first round of chemotherapy among womenwith ovarian cancer. Here, the levels of the pleural markers for cancer bio markers, before and after thechemotherapy were tested among ovarian cancer patients. The biochemical indices may be of use indeciphering the relation between cancer relapse and platinum retrieval. The pleural analy

APA, Harvard, Vancouver, ISO, and other styles

16

Roberts, Lesley F., Pascal Lambert, Mark W. Nachtigal, Alon D. Altman, and Erin Dean. "Ovarian Cancer in the Older Manitoban Population—Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study." Current Oncology 31, no. 3 (2024): 1348–58. http://dx.doi.org/10.3390/curroncol31030102.

Full text

Abstract:

Background: In Canada, individuals with gynecologic reproductive organs (ovaries, fallopian tubes, uterus) over the age of 70 comprise a large proportion of epithelial ovarian cancer patients. These patients often have co-morbidities, polypharmacy, or decreased functional status that may impact treatment initiation and tolerance. Despite this, there is limited evidence to guide treatment for older patients diagnosed with ovarian epithelial carcinoma. Methods: This is a retrospective study with data from Manitoba, Canada. The data were obtained from the Manitoba Ovarian Cancer Database, the Man

APA, Harvard, Vancouver, ISO, and other styles

17

Pullen, Richard L. "Ovarian cancer." Nursing 54, no. 6 (2024): 17–28. http://dx.doi.org/10.1097/nsg.0000000000000002.

Full text

Abstract:

Abstract: Ovarian cancer, a leading cause of cancer deaths, poses challenges due to insidious development and vague signs and symptoms. Risk factors include age, reproductive history, genetic mutations, and environmental factors. Treatment involves surgery, chemotherapy, and targeted therapy, with nursing interventions focusing on symptom management and supportive care.

APA, Harvard, Vancouver, ISO, and other styles

18

Deppe, Gunter, and Peter Baumann. "Advances in ovarian cancer chemotherapy." Current Opinion in Oncology 12, no. 5 (2000): 481–91. http://dx.doi.org/10.1097/00001622-200009000-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Anastasia, Paula. "Intraperitoneal Chemotherapy for Ovarian Cancer." Oncology Nursing Forum 39, no. 4 (2012): 346–49. http://dx.doi.org/10.1188/12.onf.346-349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ozols, R. F. "Optimum chemotherapy for ovarian cancer." International Journal of Gynecological Cancer 10, s1 (2000): 33–37. http://dx.doi.org/10.1046/j.1525-1438.2000.99508.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Park, Tjoung-Won, and Walther C. Kuhn. "Neoadjuvant chemotherapy in ovarian cancer." Expert Review of Anticancer Therapy 4, no. 4 (2004): 639–47. http://dx.doi.org/10.1586/14737140.4.4.639.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Trimbos, J. Baptist, and Petra Timmers. "Chemotherapy for early ovarian cancer." Current Opinion in Obstetrics and Gynecology 16, no. 1 (2004): 43–48. http://dx.doi.org/10.1097/00001703-200402000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hamilton, Chad A., and Jonathan S. Berek. "Intraperitoneal chemotherapy for ovarian cancer." Current Opinion in Oncology 18, no. 5 (2006): 507–15. http://dx.doi.org/10.1097/01.cco.0000239892.21161.18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Robinson, William R., Erica K. Perry, Julie Beyer, and Christy Lieberenz. "Intraperitoneal chemotherapy for ovarian cancer." Community Oncology 7, no. 2 (2010): 67–72. http://dx.doi.org/10.1016/s1548-5315(11)70556-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Omura, GeorgeA. "CHEMOTHERAPY FOR ADVANCED OVARIAN CANCER." Lancet 330, no. 8560 (1987): 689. http://dx.doi.org/10.1016/s0140-6736(87)92478-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hofstra, L. S., E. G. E. de Vries, N. H. Mulder, and P. H. B. Willemse. "Intraperitoneal chemotherapy in ovarian cancer." Cancer Treatment Reviews 26, no. 2 (2000): 133–43. http://dx.doi.org/10.1053/ctrv.1999.0152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Coukos, George, and Stephen C. Rubin. "CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER." Obstetrics & Gynecology 91, no. 5, Part 1 (1998): 783–92. http://dx.doi.org/10.1097/00006250-199805000-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kaye, SB. "Chemotherapy for recurrent ovarian cancer." Lancet 361, no. 9375 (2003): 2094–95. http://dx.doi.org/10.1016/s0140-6736(03)13726-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Walker, Joan L. "Intraperitoneal chemotherapy for ovarian cancer." Gynecologic Oncology 142, no. 1 (2016): 1–2. http://dx.doi.org/10.1016/j.ygyno.2016.06.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Neijt, J. P. "Ovarian cancer: Progress in chemotherapy." European Journal of Cancer 33 (September 1997): S140. http://dx.doi.org/10.1016/s0959-8049(97)85184-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Pignata, Sandro, Lucia Cannella, Davide Leopardo, Carmela Pisano, Giovanni Salvatore Bruni, and Gaetano Facchini. "Chemotherapy in epithelial ovarian cancer." Cancer Letters 303, no. 2 (2011): 73–83. http://dx.doi.org/10.1016/j.canlet.2011.01.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Cruickshank, D. J. "Chemotherapy in advanced ovarian cancer." BMJ 303, no. 6812 (1991): 1269. http://dx.doi.org/10.1136/bmj.303.6812.1269-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Izard, M. "Chemotherapy in advanced ovarian cancer." BMJ 304, no. 6819 (1992): 119. http://dx.doi.org/10.1136/bmj.304.6819.119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Stewart, L. A., D. Guthrie, M. K. Parmar, and C. J. Williams. "Chemotherapy in advanced ovarian cancer." BMJ 304, no. 6819 (1992): 119. http://dx.doi.org/10.1136/bmj.304.6819.119-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Friberg, Gregory, and Gini Fleming. "Intraperitoneal chemotherapy for ovarian cancer." Current Oncology Reports 5, no. 6 (2003): 447–53. http://dx.doi.org/10.1007/s11912-003-0004-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Takuma, Hayashi, Abiko Kaoru, Yamaguchi Ken, Hamanishi Junzo, Mandan Masaki, and Konishi Ikuo. "Treatment of Ovarian Cancer First Line Chemotherapy or Targeted Therapy for Recurrent Cases." International Journal of Trend in Scientific Research and Development 4, no. 3 (2020): 332–34. https://doi.org/10.5281/zenodo.3892647.

Full text

Abstract:

Ovarian cancer is the seventh most common gynecological cancer worldwide, ovarian cancer is the eighth leading cause of cancer death in women. In recent years, the number of ovarian cancer cases has been increasing in Japan, more than 9,000 women are diagnosed with ovarian cancer each year. The 5 year survival rate is 58 , the lowest among gynecological cancers, 4,758 ovarian cancer deaths in 2012. That is, it is reported that about one in two ovarian cancer patients has died. Because it is difficult to cure recurrent ovarian cancer, treatment is used to prolong life and improve quality of lif

APA, Harvard, Vancouver, ISO, and other styles

37

Pokhriyal, Ruchika, Roopa Hariprasad, Lalit Kumar, and Gururao Hariprasad. "Chemotherapy Resistance in Advanced Ovarian Cancer Patients." Biomarkers in Cancer 11 (January 2019): 1179299X1986081. http://dx.doi.org/10.1177/1179299x19860815.

Full text

Abstract:

Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients ei

APA, Harvard, Vancouver, ISO, and other styles

38

Bhugwandass, C. S., J. M. A. Pijnenborg, B. Pijlman, and N. P. M. Ezendam. "Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry." Current Oncology 23, no. 6 (2016): 556. http://dx.doi.org/10.3747/co.23.3243.

Full text

Abstract:

Background There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment.Methods All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study. Patients were requested to complete questionnaires, including the cancer-specific (qlq-C30) and ovarian cancer-spe

APA, Harvard, Vancouver, ISO, and other styles

39

Yan, Zhipeng, Zhihong Jin, Hongying Sui, Kehong Peng, and Caixia Shi. "Bruceine D Sensitizes Human Ovarian Cancer Cells to Paclitaxel Through JNK and STAT3 Signal Regulation." Revista Brasileira de Farmacognosia 32, no. 2 (2022): 257–65. http://dx.doi.org/10.1007/s43450-022-00243-z.

Full text

Abstract:

AbstractExploring novel regimens is essential to ensure the efficacy of paclitaxel-based chemotherapy in epithelial ovarian cancer. Brucea javanica (L.) Merr., Simaroubaceae, oil emulsion benefits the patients who received sequential chemotherapy, and bruceine D is identified as the major active tetracyclic quassinoid. On this premise, we explored the potential effects and related molecular mechanisms of bruceine D on epithelial ovarian cancer cells. Our study indicated an inhibitory effect of bruceine D treatment in epithelial ovarian cancer cells. Increased cell apoptosis and cancer stem cel

APA, Harvard, Vancouver, ISO, and other styles

40

Burstein, Harold J., Christina Lacchetti, Holly Anderson, et al. "Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression." Journal of Clinical Oncology 34, no. 14 (2016): 1689–701. http://dx.doi.org/10.1200/jco.2015.65.9573.

Full text

Abstract:

Purpose To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor–positive breast cancer. Methods ASCO convened an Update Panel and conducted a systematic review of randomized clinical trials investigating ovarian suppression. Results Two trials investigating the addition of ovarian suppression to tamoxifen did not show an overall clinical benefit for ovarian suppression. Nonetheless, the addition of ovarian suppression to standard

APA, Harvard, Vancouver, ISO, and other styles

41

Kulal, Santhosha, Manjunath G N, and Abhay K. Kattepur. "Uninvited Guest in the H ouse: A Rare Case of Metastatic Gallbladder Cancer." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 13, no. 4 (2023): 133–35. http://dx.doi.org/10.58739/jcbs/v13i4.23.8.

Full text

Abstract:

Gallbladder cancer is a rare malignancy. About 1–2% of surgical specimens demonstrated a gallbladder cancer as an incidental finding. Metastasis to ovaries by biliary origin, known as Krukenberg tumour, though known, is infrequent. It can mimic clinically and morphologically, as a primary ovarian tumour challenging the diagnosis. Diagnosis of secondary ovarian tumours though its challenging often misdiagnosed as primary ovarian cancer, specifically mucinous adenocarcinomas. The distinction from the latter is essential, as it requires different treatment. Immunohistochemistry plays an important

APA, Harvard, Vancouver, ISO, and other styles

42

Kashyap, Poonam. "Ovarian tumor: a review." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10, no. 9 (2021): 3657. http://dx.doi.org/10.18203/2320-1770.ijrcog20213510.

Full text

Abstract:

Ovarian cancers are the 7th most common cancers in women. It is found more commonly in elderly age group. The survival depends on the stage of diagnosis and many of the patients present in advanced disease when the prognosis becomes dismal. The dilemma is to differentiate them from benign disease so that the unwanted laparotomies could be saved. Biomarkers and radiological classification may play a role in differentiating benign from malignant and deciding on the management. There is no screening method to diagnose ovarian cancers and the patient presents with nonspecific complaints missing th

APA, Harvard, Vancouver, ISO, and other styles

43

Li, Caiyu, Liming Tan, and Weihua Zhou. "Meta-analysis of Clinical Efficacy of Metformin Combined with Chemotherapy in the Treatment of Ovarian Cancer." Journal of Clinical Medicine Research 3, no. 1 (2022): 25. http://dx.doi.org/10.32629/jcmr.v3i1.709.

Full text

Abstract:

Objective — To systematically evaluate the clinical efficacy of metformin combined with chemotherapy in the treatment of patients with ovarian cancer. Methods — Methods: Search Pubmed, Embase, Web of science, Cochrane Library database, and screen the literature of randomized controlled trials and cohort studies of metformin combined with chemotherapy in the treatment of ovarian cancer, and use Revman5.2 software to conduct meta-analysis to compare metformin combined with chemotherapy (experimental Group) or chemotherapy alone (control group) for the treatment of ovarian cancer. Results — A tot

APA, Harvard, Vancouver, ISO, and other styles

44

Rutuja, P. Nirmal*1 Rutuja Jogdande2 Jaya Kamble3 Pritam Solakhe4 Nilesh B. Chougule5. "Recent And Advance Study On Anticancer Drugs." International Journal in Pharmaceutical Sciences 2, no. 1 (2024): 788–801. https://doi.org/10.5281/zenodo.10581149.

Full text

Abstract:

In this review, we address some of the current issues and the potential for the future of cancer therapy while highlighting the key concepts. Globally, cancer is the main issue pertaining to public health.Radiation, surgery, and chemotherapy are the most prevalent kinds of cancer treatments that are currently offered. Both Carboplatin and Paclitaxel are commonly used anti-cancer medications, but they work in different ways.Many cancers, such as those of the breast, ovaries, lungs, brain, and prostate, are treated with paclitaxel. Carboplatin is a platinum-based chemotherapy drug that is freque

APA, Harvard, Vancouver, ISO, and other styles

45

Elleray, Rebecca, Cong Chen, and Sean Kehoe. "A population registry trend analysis of neoadjuvant chemotherapy and incidence of ovarian, peritoneal and fallopian tube carcinomas in England 2004-2015." Journal of Clinical Oncology 35, no. 15_suppl (2017): e17037-e17037. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17037.

Full text

Abstract:

e17037 Background: Two important developments in ovarian cancer have occurred over the last decade: i) EORTC 55971 and CHORUS trials reporting neoadjuvant chemotherapy as a management strategy in advanced disease and ii) recognition of fallopian tubes as the origin of many ovarian cancers. This study examines how these have impacted on care and registry data. Methods: The National Cancer Registry and Analysis Service (NCRAS) database identified women registered with ovarian, peritoneal and fallopian tube carcinomas during 2004-15. Treatment was defined as surgical intervention or chemotherapy

APA, Harvard, Vancouver, ISO, and other styles

46

Lee, Heejin, Jun Woo Kim, Dae Kyung Kim, et al. "Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells." International Journal of Molecular Sciences 21, no. 7 (2020): 2327. http://dx.doi.org/10.3390/ijms21072327.

Full text

Abstract:

Drug resistance in epithelial ovarian cancer (EOC) is reportedly attributed to the existence of cancer stem cells (CSC), because in most cancers, CSCs still remain after chemotherapy. To overcome this limitation, novel therapeutic strategies are required to prevent cancer recurrence and chemotherapy-resistant cancers by targeting cancer stem cells (CSCs). We screened an FDA-approved compound library and found four voltage-gated calcium channel blockers (manidipine, lacidipine, benidipine, and lomerizine) that target ovarian CSCs. Four calcium channel blockers (CCBs) decreased sphere formation,

APA, Harvard, Vancouver, ISO, and other styles

47

Chen, Yuh-Ling, Tse-Ming Hong, and Yu-Yi Wen. "Abstract 4318: CD24 enhances cisplatin resistance in ovarian cancer by suppressing autophagy." Cancer Research 84, no. 6_Supplement (2024): 4318. http://dx.doi.org/10.1158/1538-7445.am2024-4318.

Full text

Abstract:

Abstract Ovarian cancer is one of the most common gynecological cancers with the highest mortality rate. Most patients are diagnosed with advanced disease and will relapse due to chemoresistance. CD24, a highly glycosylated GPI-anchored membrane protein. Recent studies have shown that CD24 expression is significantly up-regulated in ovarian cancer and is associated with chemotherapy resistance, and CD24 also plays an inhibitory role in tumor immunity by binding to Siglec-10 on macrophages. However, the molecular mechanisms of how CD24 affects chemotherapy resistance in ovarian cancer remain un

APA, Harvard, Vancouver, ISO, and other styles

48

Morrison, Jo. "Advances in the understanding and treatment of ovarian cancer." British Menopause Society Journal 11, no. 2 (2005): 66–71. http://dx.doi.org/10.1258/136218005775544534.

Full text

Abstract:

In England and Wales, ovarian cancer is responsible for more deaths than all other gynaecological cancers combined. Unlike cervical cancer, there is no effective population screening programme and the majority of women will present when the disease has spread beyond the ovaries. Current first-line management involves surgical debulking, followed by platinum-based chemotherapy. However, most women will relapse and the five-year survival rate is 20–30%. Novel therapies, based on an increasing understanding of the molecular biology of cancers, are being developed and evaluated in clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

49

Santoso, Hendra, Syahrul Rauf, and Masita Fujiko. "Hubungan Kadar Trombosit Dan Neutrofil Antara Kanker Ovarium Tipe Epitelial Rekuren dan Nonrekuren." Indonesian Journal of Obstetrics & Gynecology Science 5, no. 1 (2022): 39–49. http://dx.doi.org/10.24198/obgynia/v5n1.323.

Full text

Abstract:

Tujuan: Menganalisis hubungan kadar trombosit dan neutrofil terhadap rekurensi kanker ovarium. Metode: Penelitian observasi case control. Data dan sampel darah diambil dari perempuan penderita kanker ovarium tipe epitelial rekuren dan tidak rekuren sebanyak 117 orang. Data yang diambil berupa usia, paritas, status menopause, serta hasil laboratorium darah rutin saat sebelum kemoterapi dan pasca kemoterapi 6 kali. Data diuji dengan analisis independent sample t test, uji Mann Whitney, analisis korelasi, serta analisis regresi logistik biner. Hasil: Terdapat hubungan yang signifikan antara kadar

APA, Harvard, Vancouver, ISO, and other styles

50

Kim, Seongmin, Sanghoon Lee, Hyun-Tae Park, Jae-Yun Song, and Tak Kim. "Genomic Consideration in Chemotherapy-Induced Ovarian Damage and Fertility Preservation." Genes 12, no. 10 (2021): 1525. http://dx.doi.org/10.3390/genes12101525.

Full text

Abstract:

Chemotherapy-induced ovarian damage and fertility preservation in young patients with cancer are emerging disciplines. The mechanism of treatment-related gonadal damage provides important information for targeting prevention methods. The genomic aspects of ovarian damage after chemotherapy are not fully understood. Several studies have demonstrated that gene alterations related to follicular apoptosis or accelerated follicle activation are related to ovarian insufficiency and susceptibility to ovarian damage following chemotherapy. This may accelerate follicular apoptosis and follicle reservoi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!